导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.27% | 2875/4750 |
| 近一周 | -2.18% | 1402/5436 |
| 近一月 | -4.13% | 2231/5395 |
| 近一季 | -7.19% | 2308/5185 |
| 近半年 | -2.51% | 1920/4896 |
| 近一年 | 0.36% | 2575/4344 |
| 近两年 | 42.86% | 1741/2945 |
| 近三年 | 26.31% | 1218/2246 |
| 成立以来 | 24.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.25% 3574/4961 |
12.11% 2226/5312 |
- - |
- - |
| 2025 | 20.07% 2152/4813 |
-0.85% 2435/3635 |
2.35% 1623/4076 |
17.92% 2398/4524 |
0.34% 2054/4813 |
| 2024 | 15.56% 911/3463 |
2.96% 651/2808 |
-0.91% 869/3014 |
14.97% 1856/3129 |
-1.47% 1715/3463 |
| 2023 | -8.68% 1045/2656 |
4.40% 964/2280 |
-3.79% 901/2385 |
-2.86% 771/2515 |
-6.41% 1758/2655 |
| 2022 | -21.56% 1040/2207 |
-13.88% 860/1919 |
6.88% 585/2016 |
-13.68% 950/2113 |
-1.27% 1688/2208 |
| 2021 | -3.39% 903/1822 |
-2.92% 725/1255 |
4.04% 931/1330 |
-5.86% 871/1466 |
1.60% 865/1822 |
| 2020 | 23.03% 659/1250 |
-11.26% 828/1028 |
12.78% 671/1067 |
10.61% 531/1164 |
11.14% 561/1184 |
| 2019 | - - |
- - |
- - |
- - |
6.57% 591/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 工银沪深300ETF联接A VS. 长安沪深300非周期A(740101) |